A review of the efficacy of the Milwaukee Protocol in the treatment of ketoacidosis in pediatric intensive care unit patients at Rebro Hospital between 2009-2014 by Malik, Mohammad Imran Khan
UNIVERSITY OF ZAGREB  
SCHOOL OF MEDICINE 
 
Mohammad Imran Khan Malik 
 
 
A review of the efficacy of the Milwaukee 
protocol in the treatment of ketoacidosis in 
pediatric Intensive Care Unit patients at Rebro 
hospital between 2009-2014. 
 
 
 
 
 
GRADUATE THESIS 
 
Zagreb, 2014 
UNIVERSITY OF ZAGREB  
SCHOOL OF MEDICINE 
 
Mohammad Imran Khan Malik 
 
 
A review of the efficacy of the Milwaukee 
protocol in the treatment of ketoacidosis in 
pediatric Intensive Care Unit patients at Rebro 
hospital between 2009-2014. 
 
 
 
 
 
GRADUATE THESIS 
 
Zagreb, 2014 
This graduation paper has been completed at the Department of Paediatrics at the 
University Hospital Centre Zagreb (Rebro hospital) under the supervision of Dr. sc. 
Mario Ćuk and was submitted for evaluation during the academic year 2013 /2014. 
 
 
 
 
 
 
 
 
 
 
 
 
 
LIST OF TABLES 
Table 1: DKA laboratory diagnosis criteria 
Table 2: Classification of DKA. Modified from Kliegman et al. Nelson Textbook of Pediatrics, 
2011. 
Table 3: Table 3: Summary of key data of patients admitted to pediatric ICU at Rebro hospital. 
 
LIST OF FIGURES 
Figure 1: DKA pathogenesis. 
Figure 2: Ketone bodies: showing formation of negatively charged conjugate bases of the 
ketoacids. The conjugate bases cause the increased anion gap in DKA metabolic acidosis. 
Figure 3: Algorithm of key steps in DKA pathophysiology. Colour coded to highlight the two 
areas that treatment should target: metabolic acidosis and hyperglycemia.  
Figure 4: True sodium level calculations for glucose levels above 100mg/dL (5.6mmol/L). 
Figure 5: Goals of DKA management 
Figure 6: Diabetic ketoacidosis treatment: Milwaukee protocol. Modified from Kliegman et al. 
Nelson Textbook of Paediatrics. 2011 p.1979 
Figure 7: DKA incidence between 1
st
 January 2009 – 30th June 2014. 
 
 
  
 
LIST OF ABBREVIATIONS 
 
DKA ..............Diabetic Ketoacidosis 
CE...................Cerebral oedema  
DMI ...............Diabetes Mellitus type I  
DMII .............Diabetes Mellitus type II 
IR…………..Insulin receptor 
AA.................Acetoacetate 
BHB...............Beta-hydroxybutyrate 
U................... Unit 
ICU…………Intensive Care Unit 
IV…………..Intravenous  
MP………....Milwaukee protocol 
SC………….Subcutaneous 
O……………Oxygen 
H
+…………… Proton 
K
+…………….Potassium 
Na
+…………..Sodium 
HCO3………Bicarbonate 
CO2……….. Carbon dioxide 
PO4
2-……….. Phosphate 
kg .………… Kilogram 
mmol………. Millimole 
mEq………… Milliequivalent 
[ ]…………….Concentration 
L……………. Litre 
↑……………. Increase  
↓…………… Decrease 
LR……………Lactated ringer 
pC02…….Partial pressure of Carbon dioxide 
NaCl…………Sodium chloride 
hr……………Hour 
TABLE OF CONTENTS 
1.0 SUMMARY...............................................................................................................................1 
2.0 LITERATURE REVIEW..........................................................................................................3 
2.1 Defining DKA...............................................................................................................3 
2.1.1 Glucose…………........................................................................................4 
2.1.2 Insulin…………..........................................................................................4 
2.2 Pathophysiology of DKA..............................................................................................5 
2.3 Epidemiology of DKA……..........................................................................................9 
2.4 Clinical picture of DKA................................................................................................9 
2.4.1 Laboratory values ………….....................................................................10 
2.5 Treatment of DKA……………………………...........................................................12 
2.5.1 Milwaukee protocol………………………………………………….......13 
2.5.2 Cerebral oedema……………………………..…………………………. 15 
2.5.3 Bicarbonate therapy.................................................................................. 16 
3.0 PATIENT DATA REVIEW…………………………………………………………………17 
4.0 CONCLUSION........................................................................................................................23 
5.0 ACKNOWLEDGEMENTS.....................................................................................................24 
6.0 REFERENCES........................................................................................................................25 
7.0 BIOGRAPHY..........................................................................................................................26
1 
 
1.0 SUMMARY 
Title: A review of the efficacy of the Milwaukee protocol in the treatment of keto-
acidosis in paediatric intensive care unit patients at Rebro hospital between 2009-2014. 
Name: Imran Malik 
 
Ketoacidosis is a condition of increased pathologic levels of ketone bodies in the body 
that results in the acidification of blood. The major types are alcoholic and diabetic 
ketoacidosis. DKA is defined as an arterial pH < 7.25, serum bicarbonate < 15mEq/L and 
elevated ketones in serum or urine (Marcdante et al. 2010). Other sources define DKA with 
the above criteria but also additionally a glucose concentration >11mmol/L (>200mg/dL) 
together with glucosuria and ketouria (Rosenbloom 2010) (Wolfsdorf et al. 2009).  
Paediatric patients reviewed at Rebro Hospital (University Hospital Centre Zagreb) 
were all treated for the latter condition. This thesis surmises the treatment methodology as 
devised by the Milwaukee Protocol and attempts to evaluate the efficacy of this treatment 
over the period of 01.01.2009 – 30.06.2014.  
Patient records were obtained from the Rebro Hospital archives and details on ICU 
treatment of diabetic ketoacidosis were evaluated. Personal identifying data was removed. 
During the period analysed patient archive records indicate that 21 patients were admitted 
into the paediatric ICU at University Hospital Centre Zagreb for treatment of DKA. 20 
patient records were obtained, of which 19 patients were confirmed to have been treated 
according to the Milwaukee protocol. It was assumed that the other 2 cases were as well as it 
is the hospital policy to follow this protocol. Successful treatment was observed in 100% of 
cases. Success is defined here as the sufficient control of the metabolic derangement as 
indicated by meeting the following Milwaukee Protocol exit criteria: HCO3 > 15 mmol/l, pH 
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> 7.30, Na: 135-145 mmol/l with no emesis (Kliegman et al. 2011) and resulting in discharge 
of patient from ICU. 
Conclusions drawn include the need for a coordinated response based on a hospital 
wide policy with clear pro forma. Management of DKA condition should be under the 
supervision of centres that have experience dealing with the issue; at University hospital 
Zagreb (Rebro hospital) this should be the paediatric ICU centre. Vital signs, neurologic 
status and laboratory indices for DKA biomarkers should be monitored at timely intervals as 
to prevent further adverse effects. It is suggested that data be recorded electronically and on 
ICU forms designed to record DKA. In cases of cerebral oedema, Rebro hospital should 
develop protocols to be able to identify CE development early on and treat rapidly with 
mannitol or hypertonic IV saline. With respect to treatment fluid resuscitation should begin 
before intravenous insulin administration (0.1. U/Kg/hr), beginning with a bolus of 10-
20mL/kg 0.9% saline, followed by a maintenance supply of 0.45% saline that should address 
5-10% of fluid loss from dehydration (Rosenbloom 2010) (Kliegman et al. 2011). 
 
Keywords: Diabetic Ketoacidosis (DKA), Milwaukee Protocol, cerebral oedema, 
children, prevention, treatment 
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2.0 LITERATURE REVIEW 
2.1 Defining DKA 
DKA can be defined as a state of aberrant catabolism triggered by hyperglycaemia, in 
itself induced by absolute or relative deficiency of insulin (Kliegman et al. 2011). A result of 
which, leads to a ketosis, a rise in ketoacids in the blood causing metabolic acidosis with an 
elevated anion gap (Marcdante et al. 2010).  
Table 1. DKA biochemical diagnosis criteria 
HYPERGLYCEMIA Blood glucose: > 200mg/dL ( >11mmol/L) 
KETOSIS Elevated serum or urine ketones 
Serum ketones > 5mEq/L 
ACIDOSIS Arterial pH < 7.25          Serum HCO3
-
 < 15mEq/L (15mmol/l) 
 
DKA is a characterising feature of undiagnosed new-onset DM I. It is also observed 
in DM I patients who fail to meet their bodies requirement of insulin in a state of increased 
counter- regulatory hormones (glucagon, GH, catecholamines and cortisol). Examples of a 
failure to meet the body’s need for insulin in a DM I patient include inadequate insulin dosing 
or unaccounted states of increased insulin demand such as suffering from an concomitant 
illness. Patients with DM II have also been noted to develop DKA. DKA is an acute medical 
emergency that warrants urgent attention and treatment with insulin and rehydration therapy.  
An anabolic hormone, the role of insulin is to regulate glucose and lipid metabolism 
along with its stress-responsive catabolic counterparts: glucagon, growth hormone, 
catecholamines and cortisol. DKA development is intrinsically tied in with dysregulation of 
these systems: the relative deficiency of insulin coupled with a relative excess of catabolic 
hormones. DKA that ensues is an example of a super-fasted state.  
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2.1.1 Glucose 
A breakdown product of food as well as formed endogenously, increased levels of 
serum glucose stimulates insulin production. Once glucose has entered insulin activated cells, 
it can be metabolised to pyruvate via glycolysis or stored as glycogen in muscle and liver 
cells in the process of glycogenesis. Pyruvate is a key metabolite utilised in the Krebs cycle 
in mitochondria for the formation of ATP, the energy currency of cells (Hall 2006). The 
hyperglycaemia of DKA results in osmotic diuresis, and often subsequent volume depletion 
and significant loss of electrolytes: potassium, sodium and phosphate (Kliegman et al. 2011). 
 
2.1.2 Insulin 
Secreted by the pancreas in response to breakdown products of digested food, insulin 
binds to IR on cells. These tyrosine kinase receptors in turns trigger many protein activation 
cascades that result in the following: 1) the translocation of GLUT-4 (glucose transporter) to 
the plasma membrane of insulin sensitive cells allowing for glucose to cross an otherwise 
impermeable membrane, 2) glycogen synthesis, 3) glycolysis, 4) free fatty acid synthesis and 
inhibition of lipolysis. Insulin also stimulates protein formation and stimulates transcellular 
shifts of potassium and phosphate. 
Insulin treatment corrects the metabolic acidosis and allows for conversion of AA and 
BHB into bicarbonate, helping to rectify the acidic pH of metabolic acidosis. In patients with 
low concentrations of these ketoacids, due to urinary excretion of them, complete 
rectification of metabolic acidosis is slower as it is dependent on renal production of 
bicarbonate (Kliegman et al. 2011). 
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2.2 Pathophysiology of DKA 
In summary the anabolic hormone insulin is paramount for the energy needs of cells 
and promotes the storage of both fats and glucose as triglycerides and glycogen respectively. 
In contrast counter-regulatory hormones are involved in the catabolic processes of 
glycogenolysis, proteolysis (gluconeogenesis) and lipolysis (formation of free fatty acids and 
ketone bodies). Thus, without insulin, the body is reliant on the catabolism of glycogen, 
protein and fat to meet energy demands (Hall 2006) (Kliegman et al. 2011).   
In states of insulin deficiency compensatory mechanisms are stimulated by secretion 
of the aforementioned stress and counter-regulatory hormones: hepatic gluconeogenesis, 
glycogenolysis and lipolysis (Figure 1). Glucagon is metabolised and excessive hepatic 
glucose production occurs. However in the absence of insulin, the glucose remains locked out 
of cells and hyperglycaemia ensues. 
 
 
 
 
 
 
 
Insulin deficiency 
(relative / absolute) 
↓Anabolic 
functions  Hyperketonemia 
↑ Counter-regulatory and stress hormones  
Hyperglycemia 
Ketosis 
↑ Glucose production 
(Hepatic and renal glycogenolysis and 
gluconeogenesis) 
↑ Catabolism  
↓Cell glucose 
utilisation 
 
Figure 1. DKA pathogenesis. 
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The metabolism of fats to free fatty acids thus becomes a key source of substrate for 
the liver, along with proteins, for glucose formation. Palmitoyl-CoA, a fatty acid formed from 
beta-oxidation of fats is harnessed by the Krebs cycle to create ATP. A by-product of this 
FFA metabolism are the ketones: acetone, acetoacetate and beta-hydroxybutyrate, of which 
the latter two are ketoacids (Figure 2). Thus, along with hyperglycaemia there is an increase 
in serum FFA and acidic metabolites. 
 
Figure 2. Ketone bodies: showing formation of negatively charged conjugate bases of the 
ketoacids. The conjugate bases cause the increased anion gap in DKA metabolic acidosis. 
 
The increased serum glucose eventually exceeds renal threshold for reabsorption of 
glucose (160-180mg/dl) and glucose escapes into the urine causing an osmotic diuresis to 
develop and subsequent dehydration of the patient. This dehydration contributes to a shift of 
electrolytes from within cells to their extracellular surroundings (Figure 3).  
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The presence of ketoacids shifts the pH of blood into the acidic range and raises the 
anion gap. Lactic acidosis can also contribute to evolving metabolic acidosis in conditions of 
decreased tissue perfusion due to dehydration. Cells with H
+
/K
+
 pumps attempt to rectify the 
acidic conditions by exchanging intracellular K
+
 for extracellular H
+
 (Hall 2006). This 
increases serum K
+
, shifting K
+
 from the intracellular space to plasma but eventually leading 
to total body K
+
 depletion as the electrolyte is expelled by the kidneys. Measurements of 
plasma K
+
 (pseudo-eukalemia or pseudohyperkalemia) can thus mask the actual total body 
K
+
 depletion. And it should be noted then that clinically serum potassium concentration may 
be recorded as within the normal range, above or below in a DKA patient at diagnosis 
(Kliegman et al. 2011). Correspondingly EKG readings may indicate hyperkalaemia (peaked 
T wave) or hypokalaemia (U wave or low T wave) (Raghavan 2014).  
Total body phosphate levels are also decreased as a result of PO4
2-
 renal excretion; the 
elimination of the electrolyte is a by-product of renal concerted efforts to remove excess 
hydrogen ions. 
Vomiting and tachypnea induced by acidotic state can exacerbate dehydration by 
providing an avenue for further fluid and insensible water loss respectively. Developing DKA 
state can be masked or compensated by increasing fluid intake though eventually patients are 
unable to maintain the large fluid intake requirement required to offset it. The dehydrated 
state of the individual can lead to shock when volume depletion is large enough. Until that 
point is crossed, the degree of dehydration can be concealed by normal blood pressure 
readings and polyuria (Wolfsdorf et al. 2009). 
Hyponatremia state is also common in DKA as sodium is loss as a result of osmotic 
diuresis and in patients who are vomiting. Bicarbonate (or total CO2) is also decreased.  
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↓ Insulin 
↑Ketone bodies 
 
Metabolic acidosis 
with ↑ anion gap 
Serum K + ↑ 
↑ Glucose 
 
↓ Total body 
phosphate 
↓Total body 
electrolytes  
(Na+, K +, Mg2+, PO4
2-) 
↑BUN 
Hyperglycemia 
Hypertonic 
dehydration 
Osmotic diuresis 
Activated renin-
angiotensin- 
aldosterone axis 
Hypoxia 
 
Figure 3. Algorithm of key steps in DKA pathophysiology. Colour coded to highlight the areas that treatment should target: dehydration, 
metabolic acidosis and hyperglycaemia. Key: ↑ increased ↓ decreased. 
Lactic acidosis 
Renal failure 
↑ Creatinine 
↓GFR  
Shock 
↓ECF volume  
↑ plasma 
osmolality 
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2.3 Epidemiology of DKA 
At risk groups include new-onset and insulin dose omitting diabetics as well as those 
with poorly controlled concurrent illnesses. In this risk category 20-40% of diabetic children 
will experience DKA (Kliegman et al. 2011). Between 1995-2003 incidence for type 1 
diabetes mellitus in Croatia, for children aged 14 and under, was 8.87/100000 person-years, 
with an average increasing annual incidence of 9% (Stipancic et al. 2008). Incidence of 
paediatric diabetic ketoacidosis in Croatia between 1995 - 2003 involved 607 cases with the 
greatest number occurring in central Croatia (247 cases) followed by southern Croatia (243). 
In this study ketoacidosis was defined as either pH < 7.3 or pH <7.3 and/or bicarbonate <15 
mmol/L (Stipančić et al. 2012). In the US DKA has a mortality rate of 2-5% (Young 2014). 
 
2.4 Clinical picture of DKA 
Initial presentation of patients with DKA includes the following features: polyuria, 
polydipsia, nausea and vomiting. Polyuria observed in this dehydrated state is due to osmotic 
diuresis and can be used to differentiate from patients with GI disorders such as 
gastroenteritis (though it should be noted infections such as gastroenteritis can instigate 
DKA). Other clinical features may include altered mental state and presenting with an acute 
abdomen-like symptomology. Abdominal pain, tenderness and distention are frequent 
symptoms, with the latter two symptoms being secondary to vomiting and paralytic ileus 
respectively. Fruity smelling breath (due to acetone) and Küssmaul breathing (deep, rapid 
respiration) is observed in DKA patients as they attempt to blow off CO2 and compensate for 
the acidosis (Kliegman et al. 2011). Glucosuria and ketouria are often present as DKA 
develops (Rosenbloom 2010). Cerebral oedema is one of the most dangerous complications 
of DKA and occurs more commonly in the paediatric population than the adult population 
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(Kitabchi and Wall 1999).  Clinical signs include altered mental status which either 
demonstrates gradual deterioration of consciousness or gradual improvement followed by 
abrupt deterioration of neurological status. Other clinical signs include incontinence, 
recurrent vomiting, severe headache with sudden onset, papilledema, seizures, 
opthalmoplegia and agitation (Kliegman et al. 2011). 
 
2.4.1 Laboratory values  
Refer to Table 1 for major criteria. Serum glucose values in hyperglycaemic DKA 
patients range from 200mg/dL to >1000 mg/dL. Serum bicarbonate levels tend to be 
<15mEq/L.  
Resembling potassium serum levels, sodium serum levels may be high, low or 
normal. In the case of sodium this is due to imbalance of sodium, insensible water losses, 
vomiting or urinary losses. But it should be noted that the measure sodium value will be 
depressed due hyperlipidaemia and hyperglycaemia. Hyperlipidaemia displaces sodium in 
most commonly used laboratory assays. In hyperglycaemia glucose exerts osmotic pressure 
in the extracellular space resulting in dilution of sodium as fluid follows from the intracellular 
space to the extracellular space (Frieda, Davidson, and Hall 2004).  So the true sodium level 
(Figure 4) can be calculated as follows for glucose levels above 100mg/dL (5.6mmol/L):  
A     [Na
+
] + glucose – 100 x 1.6      B [Na+] + glucose – 5.6 x 1.6  
100              5.6 
Figure 4. True sodium level calculations for glucose levels above 100mg/dL (5.6mmol/L). 
Key: A: glucose measure in mg/dL and B: glucose measured in mmol/L 
Thus in the case of A, sodium should increase by about 1.6mmol/L for each 
100mg/dL decline in glucose.  
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Total body stores of chloride and magnesium are also depleted (Kliegman et al. 
2011). Blood urea nitrogen (BUN) can be elevated in dehydrated patients with pre-renal 
azotaemia. Increased BUN and creatinine levels are signs of intravascular volume depletion. 
Note serum creatinine may be falsely increased where data has been recorded using 
autoanalyser methodology as ketones present interfere with the results. Leucocytosis can be 
present and left-shifted without an underlying infection. DKA can be classified (see Table 2) 
as mild, moderate or severe. With regards to treatment of DKA, in practice, these terms are 
arbitrary. Hyperamylasemia is observed in DKA patients and could be due to pancreatitis, 
though in instances where the serum lipase is not elevated it is less likely to be so (Raghavan 
2014). 
Within Croatia different criteria have been used in different hospitals to define DKA 
(Stipančić et al. 2012) and thus with University Hospital Zagreb it cannot be excluded, over 
the time frame studied, that different DKA diagnostic criteria has been employed. 
 
Table 2. Classification of DKA. Modified from Kliegman et al. Nelson Textbook of 
Paediatrics, 2011 p.1976. 
 Normal Mild Moderate Severe** 
Venous CO2 
(mEq/L)* 
20-28 16-20 10-15 <10 
Venous pH* 7.35-7.45 7.25-7.35 7.15-7.25 <7.15 
 
Clinical 
Presentation 
- Orientated, alert but 
fatigued 
Küssmaul 
breathing, 
orientated but 
somnolence; 
arousable 
Küssmaul or 
depressed 
breathing; 
somnolence to 
depressed 
sensorium to 
coma 
* Measurements for CO2 and pH are method dependent; normal range may vary.  
**Severe hypernatremia (corrected Na>150mEq/L) would be classified as severe diabetic ketoacidosis. 
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2.6 Treatment  
Management of DKA within an ICU during the first 24-48 hours or until corrected is 
advisable. Management goals are listed below in Figure 5.  
 
Figure 5. Goals of DKA management 
Chest x rays to rule out pulmonary infection. CSF studies an option. Low threshold for CT 
scanning in paediatric patients with altered mental status possibly due to CE. Note many 
changes caused by CE are seen late in the course and thus treatment measures (hypertonic 
saline or mannitol) should not be delayed in suspected CE cases.  
 
 
Correction of 
hemodynamic status with 
IV fluids 
Correction of 
hyperglycemia with 
insulin 
Correction of K and 
other electrolyte 
abnormalies 
Correction of 
lactic acidosis 
with IV fluids 
Correction of 
metabolic 
acidosis with 
insulin 
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2.6.1 Milwaukee protocol 
Having been developed over 20 years ago, the MP has an impeccable safety record in 
large clinic settings with no mortality or known neurologic sequelae in any child treated 
initially along its guidelines. Regardless of age of the child or the degree of DKA, MP has 
been designed to treat all such cases (Figure 6). The aim of MP is to correct most electrolyte 
abnormalities, pH and to rehydrate a moderately ill patient within 24 hours (Kliegman et al. 
2011).   
 An assumption is made that there is standard water deficit of 85 mL/Kg (8.5% 
dehydration). The MP corrects this deficit in the first 24 hours. When this figure is added to 
maintenance the sum is about 4L/m
2
 for children regardless of size. Milder DKA states take 
about 10-20 hours to be corrected and more severe cases around 30-36 hours (see Table 3) 
(Kliegman et al. 2011). Close monitoring is required in the implementation of MP due to the 
inherent risks correction of DKA is associated with. 
 Milwaukee Protocol exit criteria: HCO3 > 15 mmol/l, pH > 7.30, Na: 135-145 mmol/l 
with no emesis. Upon which patients can be transitioned to oral intake and SC insulin. IV is 
capped and SC insulin given with the first meal initially (Kliegman et al. 2011).  
Table 3. Fluid required for maintenance in normal children with DKA. Modified from 
Wolfsdorf et al. 2009 page 119. 
Electrolyte Average losses/kg Body weight                                     Maintenance/24 hours 
 
H20 
 
70ml 
≤10kg 
11-20kg 
>20kg 
100ml/kg/24hr 
1000ml + 50ml/kg/24hr for every kg in this range. 
1500ml + 20ml/kg/24hr of every kg above 20kg 
Na+  
6mmol 
 
                    
                   2-4mmol/100ml maintenance IV fluid 
 
K+ 
 
5mmol 
 
                   2-3mmol/100ml maintenance IV fluid 
 
Cl- 4mmol 
 
PO4
2- 0.5-2.5mmol*                     1-2mmol/100ml maintenance IV fluid 
    * Phosphate losses given as a range. 
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 Points of note include the immediate administration of insulin at the beginning of 
treatment, and that this is not delivered as a bolus but as an infusion. An insulin bolus may 
incur a state of hypoglycaemia and/or hypokalaemia. The insulin infusion is given at rate of 
0.1U/Kg/hr (Figure 6). Sodium levels should be calculated to obtain true values (Figure 4). 
Insulin is given at the beginning to catalyse the movement of glucose intracellularly as well 
as dampen down hepatic glucose production and impede movement of fatty acids to the liver 
from its surroundings (Kliegman et al. 2011). Rehydration in itself lowers glucose levels by 
increasing GFR and enhancing renal excretion of excess glucose. Osmotic diuresis ends once 
glucose goes below 180mmol/L and rehydration occurs at a quicker rate without additional 
increase in fluid infusion rate (Kliegman et al. 2011). In the first hour up to 20ml/Kg IV 
saline bolus is given to neonates of normal birth weight 1 month and older. For neonates 
approximately 10ml/kg saline is used and for underweight neonates approximately 5ml/kg is 
given. 
It should be noted that the initial bolus given is an isotonic solution without any added 
sugar. This is because the patient is in a hypertonic state and thus retains most of the initial 
infusion in the blood vessels. This way quick volume expansion is achieved (Figure 6). 
Subsequent infusions use hypotonic fluid to address the free water deficit. This ensures 
intracellular rehydration and accounts for any loss of hypotonic fluid via the urinary system. 
Because the metabolic acidosis takes longer to correct then hyperglycaemia, insulin 
infusion is dependent on the former condition rather than the latter. Once the hyperglycaemic 
state has been corrected, glucose is added to prevent hypoglycaemia developing.   
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10 - 20ml/kg IV bolus 0.9% Sodium chloride 
or Lactated Ringer solution 
 
Insulin drip at 0.05-0.1 U/kg/hr 
 
0.45% Sodium chloride infusion + 
continuous IV drip 
 
40mEq/L IV K:  
20mEq/L potassium phosphate  + 
20mEq/L potassium acetate infusions 
 
5% glucose if serum glucose <14mmol/L Maintenance (24hr):  
100ml/kg (for 1st 10kg) + 
50ml/kg (for 2nd 10kg) + 
20ml/Kg (for remaining kg) 
IV rate = 85mL/kg + maintenance – bolus 
23hr 
 
Subcutaneous insulin with oral intake 
DKA detected 
pH < 7.25; HCO3 < 15mEq/L; Elevated ketones in serum or urine 
 
1st hour 
 
2nd hour 
onwards 
 
After DKA 
resolution 
 
Figure 6. Diabetic ketoacidosis treatment: Milwaukee protocol. Modified from Kliegman et al. Nelson Textbook of Paediatrics. 2011 p.1979 
 
IV bolus is factored into the 
total fluid allowed in 1
st
 24 
hours and thus is subtracted 
here before calculating IV rate. 
 
Quick volume expansion. 
Therapy can be repeated 
but do not exceed 30ml/kg 
 
For cerebral edema: 
20% Mannitol  0.5- 
1g/kg IV push 
 
Nil per os. Monitor urine, 
emesis and neurological 
status. 
 
If K+<3mEq/L give 0.5- 1mEq/Kg 
as oral K solution or ↑IV K to 80 
mEq/L. 
No emesis; normal health. 
CO2 > 16mEq/L; pH >7.30 
Correct electrolyte abnormalities. 
 
Milwaukee exit criteria:  
 
pH > 7.30  
HCO3 > 15 mmol/l 
Na: 135-145 mmol/l  
15 
 
Complications of DKA and its treatment are numerous, but can be grouped as: 
1) Vascular: hypotension, shock, myocardial infarction, stroke, CE, acute tubular 
necrosis and renal failure 
 2) Electrolyte and glucose based: hyper/hypokalaemia, hypoglycaemia 
3) Infectious: sepsis, infections 
4) Other: aspiration pneumonia 
 
2.6.2 Cerebral oedema 
Reversal of DKA is associated with several risks such as hypokalaemia, 
hypoglycaemia and CE. CE is an important cause of morbidity and mortality in children with 
DKA. It can arise as the condition progresses as well as from as a complication of treatment. 
Risk factors are thought to be early insulin and high volume of fluid administration. However 
the international adoption of gradual rehydration protocols has not altered the incidence of 
CE in the last 15-20 years. Radiographic data upon presentation of patient’s symptoms is 
often found not be of use. Close monitoring of DKA patients’ neurological status along with 
immediate availability of mannitol for use in suspected CE patients. Effective serum 
osmolality = 2 x [Uncorrected Na] + [Glucose]. Severely hypernatremic patients (corrected 
serum >15mEq/L) may have more success being treated with isotonic fluids for a longer time 
period and at a more measured rate of rehydration. Note sodium should steadily increase with 
therapy and decreasing sodium levels may point toward an excessive build-up of free water 
and an augmented risk of CE.    
Treatment protocol involves mannitol (fig. 5), decreasing maintenance IV fluid rate to 
70%, elevation of head and considering intubation and controlled hyperventilation- the latter 
causing vasoconstriction due to induced hypocarbia state (Rosenbloom 2010). 
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2.6.3 Bicarbonate therapy 
Current guidelines restrict the use of bicarbonate in DKA to severe cases. In general 
base therapy in DKA is a controversial topic that warrants further study. Evidence provides 
little support to idea that base therapy improves patient outcome, but does show that there are 
a host of risks associated with its implementation. These include causing hypernatremia, 
volume overload and alkalemia. A rapid change in pH to alkalemia from acidemia can lead to 
potassium and phosphate depleted states. Patients with underlying respiratory pathologies are 
at risk from accumulating CO2 generated by bicarbonate therapy including compromised 
cellular function- CO2 can diffuse into cells and lower the intracellular pH (Kliegman et al. 
2011). It should be noted that metabolic alkalosis in DKA patients, treated with bicarbonate 
therapy and pre-treated with insulin, is not common in those with normal renal function. 
While insulin does allow ketoacids to form bicarbonate, often there is significant enough loss 
of ketoacids in urine to prevent a pathological amount of bicarbonate generation to occur. 
Patients with impaired renal function or volume depletion, factors that impede kidney 
function, are the major risk factors for metabolic alkalosis (Kliegman et al. 2011).  
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3.0 PATIENT DATA REVIEW 
In Croatia paediatric patients are defined as those under the age of 18. At Rebro hospital a 
total of 21 cases of diabetic ketoacidosis were recorded between 1
st
 January 2009 – 30th June 
2014. All paediatric patients diagnosed with DKA were treated in the paediatric ICU wing. 
Research results were conducted via database search and data was obtained from the Rebro 
hospital archives. It was assumed that all paediatric DKA cases were recorded correctly into 
the archive database. Of the 21 positive results for medical cases of DKA, 20 patient files 
were retrieved. One patient file was missing and another lacked ICU data on treatment (9 and 
20). Only a log of their entry into the hospital and names were recorded here (Table 3). 
Figure 7 shows that the greatest number of cases occurred in 2009, however it should be 
noted that in 2014 the frequency thus far is 0.5 cases per month, higher than for 2009 (0.42 
cases per month).  
Figure 7. DKA incidence between 1
st
 January 2009 – 30th June 2014.  
  
0 
1 
2 
3 
4 
5 
6 
2009 2010 2011 2012 2013 2014 
Frequency  
of cases 
 
Year 
18 
 
Table 4: Summary of key data of patients admitted to pediatric ICU at Rebro hospital.   
Year Case Pt Age Pt Wt 
(kg) 
Length 
of MP 
treat-
ment 
(hours) 
Lowest 
pH  
pC02 
(kPa) @  
time of 
lowest 
pH 
BE 
(mmol/l) 
@ time of 
lowest pH 
Lowest serum 
bicarbonate  
(mmol/l) 
Peak hyper-
glycemia 
(mmol/l) 
Lowest/Highest 
kalaemia outside 
of normal range 
(mmol/l) 
 
Lowest/Highest 
natremia  outside 
of normal range 
(mmol/l) 
NaCl 
or LR 
Comorbidities and notes 
2
0
0
9 
 
1 9.9 53 45 7.06//24 2.3 -23.6 4.8//26 >27.8 ↓// - NA/6.5 NA NaCl DMI 
2 17.7 87 31 7.15//21 2.5 -22.3 6.6//21 >27.8 ↓// - NA/5.9 NA NaCl DMI 
3 0.18 13 15 7.11//9 2.3 -24.1 4.9//12 >27.8 ↓↑↓// - 2.9/NA 126/NA NaCl DMI 
4 12.3 35 9 7.13/8 1.7 -24.9 4.3//8 22.8↓// - NA 134/NA NaCl DMI; Autoimmune thyroiditis 
5 7.3 27 16 6.99/- 2.5 - 26.8 3.1//- 26.3↓// - NA 127/NA NaCl DMI 
2
0
1
0 6 9.1 30 14 7.08//8 2.9 -23.5 6.5//8 >27.8 ↓// - NA/6.3 133/NA NaCl DMI 
7 3.7 13 14 7.15↑//- 0.85 -23.4 7.0↑//- 17.1 ↓// - NA NA NaCl DMI; Herpes labialis 
 
2
0
1
1 
8 1.9 10 17 7.04//14 2.1 -24.5 4.1//16 >27.8 ↓// - NA/6.9 NA NaCl DMI 
9 1.0           DMI – missing ICU data 
10 17.7 72.4 45 6.89//43 1.9 - 3.0 //43 >27.8 ↓// - NA/5.9  NA NaCl DMI; Autoimmune thyroiditis; 
Hyperlipidemia  
11 14.5 59 12 7.12//10 2.3 -21.8 5.5//11 17.7 ↓// - NA/5.8 NA NaCl DMI; Graves disease;  Primary 
hypothyroidism; Hyperlipidaemia 
2
0
1
2 
12 9.5 60 65 6.98//61 1.6 - <3.0↑//65 17.8 ↓// - 2.5/5.3 127/146 NaCl DMI; Pancreatitis; Cushing 
syndrome; Secondary aplastic 
anemia; Osteoporosis; 
Hypertension; Juvenile idiopathic 
arthritis (systemic form) 
13 8.11 17 16 6.91↑//- 1.5 - <3.0↑//- 20.3 ↓// - NA/6.4 NA NaCl DMI; Celiac disease; Turner 
syndrome; Autoimmune thyroiditis 
14 8.2 35 41 6.92↑//- 1.7 - <3.0↑//- >27.8 ↓// - NA 133/NA NaCl DMI; possible celiac disease;  
2
0
1
3 
15 10.2 40 12 7.08↑//- 1.7 -24.0 3.9↑//- 29.1 ↓//- NA/5.1 NA NaCl DMI; Suspected seizure 
16 14.7 87 28 7.06//19 3.2 -22.0 5.7//19 17.5 ↓// - NA/5.8 129/NA NaCl DMI; Autoimmune thyroiditis; 
Hyperlipidaemia 
17 7.2 18 18 7.18//3 2.9 -18.3 8.2 >27.8 ↓// - NA/5.4 NA/147.2 NaCl DMI 
18 7.11 40 37 6.99//13 1.7 - 26.5 3.0//17 16.7↓↑↓//- 3.2/5.1 NA/168.5 NaCl DMI; CE (mannitol 20%); General 
weakness; Nosebleeds; Sore throat.  
2
0
1
4 
19 12.2 65 8 6.99//21 2.5 -26.8 4.1//23 19.8 ↓// - NA NA NaCl DMI; Autoimmune thyroiditis; 
Primary hyperthyroidism 
20 4.3           Patient file missing 
21 15.2 47 22 7.02//18 2.5 -26.1 4.5//8 17.0↓↑↓// - NA NA NaCl DMI 
Key:  // = the number of hours of treatment required to bring variable back into a normal range  * = Missing patient file Age = years.months - = unknown  
NA = non applicable as within normal range  Pt = Patient Wt = weight ↑=  increased over time of treatment ↓= decreased over time of treatment  
 DMI= Diabetes Mellitus type I DMI = newly diagnosed DMI MP: Milwaukee Protocol 
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Table 4 provides a summary of the patient data obtained from the Central archives at 
Rebro Hospital. High glycaemic serum levels, low pH coupled with low bicarbonates and 
normal (or compensating) pC02 levels with elevated ketones indicate DKA. Most of the 
laboratory work up was conducted using blood sourced from capillaries, though for case 18 
data was largely sourced from venous blood. 
It is beyond the scope of this review to analyse every case in detail but what is shown 
in Table 3 validates Milwaukee protocol as an effective protocol for treating diabetic 
ketoacidosis, regardless of the range of circumstances presented. With regards to insulin and 
fluids, a fast acting insulin Actrapide and NaCl were the medicaments of choice in all cases. 
Lactated ringer was not used at all. Comorbidities were treated accordingly and CE was 
present in one case (18). 20% Mannitol (100ml) was given over the course of 30 minutes to 
correct the CE.  Cases 1 and 16 involved the same individual, 7 years apart. Case 7 lacked 
ICU data, and it is assumed to have been lost. 
DKA was treated successfully in all patients with patient records showing 13 of the 19 
cases met the exit criteria for MP while in the ICU. Of the remaining 6 cases, discharge 
letters within their patient files also confirm successful treatment. As it is the practice of the 
Paediatric department at Rebro Hospital to treat all patients within the Paediatric ICU for 
DKA, it is assumed that their full treatment occurred there. The exception to this is case 19, 
where the patient was moved to the Endocrinology ward- the reason why is unknown. In the 
cases (5, 7, 13-15) that contain ICU notes that do not meet the exit criteria set forth by the 
MP several suggestions have been listed as to why they end in such a manner. The first is that 
they did meet the exit criteria and the data was omitted accidently, intentionally or lost. 
Alternatively, physicians may have been working towards a different exit protocol criterion, 
or felt the remaining acidic pH was not of ketonic nature, but for example, due to lactic 
acidosis (those this was not supported by the last lactate readings noted). Ticks next to 
20 
 
laboratory readings, drawn in by presumably the attending physician, would suggest 
satisfaction with presented results, but what this indicates other than that is a matter of 
conjecture. 
Ketonemia, ketouria and glucosuria was observed in all patients at the beginning of 
therapy. As therapy progressed these biochemical variables diminished, and in all cases 
ketouria and ketoemia were abolished. This occurred within 6-12 hours of therapy. With 
regards to lactates and ketones, they were not recorded in Table 4 as the former had little 
impact on these cases and the latter followed a pattern of peaking at the beginning before 
being extinguished over the course of the treatment. In patient notes ketones in serum and 
urine were checked with much less frequency than other DKA variables. This is perhaps due 
to the specialist tests required or the dependency on urine production. Table 4 shows that in 
general bicarbonate levels took longer to control than pH. 
100% of the medical cases involved patients with DMI, of which over a third of cases 
(36.8%) occurred in individuals with previously undiagnosed type 1 diabetes mellitus. These 
are classic examples of absolute insulin deficiency induced DKA (Wolfsdorf et al. 2009). MP 
treatment was found to quickly positively impact blood glucose levels in all cases, lowering 
blood glucose within a day or two to below 10mmol/l. But it should be noted that within the 
ICU time frame none of the cases were controlled to within the normal range. How long it 
took to control blood glucose within the normal range is therefore listed as unknown. The 
highest blood glucose reading tended to be reading on presentation and while the general 
declining trend in blood glucose levels, both case 3, 18 and 21 demonstrated periods where 
glucose levels spiked. While in case 3 and 21 it is unclear as to why this occurred, in case 18 
it can be attributed to the mannitol infusion to treat CE, given at a time just preceding the 
spike.  
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Episodes of hyperkalemia, hyponatremia and hypernatremia (corrected within two 
hours on average) were observed as were increased lactate and creatinine levels in some 
patients. Hyperkalaemia was generally observed towards the end of therapy, though in case 
13 it was observed for much of the individual’s stay in the ICU. In this instance it was most 
likely due to the IV potassium infusion. In these cases there were no situations of 
hyponatremia or hypernatremia.  
5 out of 19 medical cases involved patients with DMI and a thyroid disease. This 
perhaps warrants further investigation. 
In general the initial readings were the most extreme, though there were several 
instances where readings worsened after the first hour due to underestimation of quantities of 
medicine required. This in turn highlights the paramount nature of close monitoring of all 
relevant biochemical variables on a frequent basis. Hourly monitoring was the most common 
observed frequency interval, though in some patient files there were time gaps larger than an 
hour. In these instances, it is assumed that this is due to poor logging of data than inattentive 
physicians as later logged data would indicate improving health status of patient. 
Readings were logged on either one of two possible ICU A4 sized forms. The first 
was a generic ICU form where DKA readings were written into hand drawn tables- drawn in 
areas of the form where one could find space. This is because this type of form was not 
designed to record DKA readings in their entirety. The second form was an update of the first 
ICU form and contained a small table that could be used for four intervals of DKA 
recordings. Because the forms used to record DKA data were not designed for this, problems 
arise in locating where or whether if all of the necessary data was written on the form/s, the 
legibility of the handwriting and the physical state that these forms are in (stained paper, 
faded ink etc.) 
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In most instances to account for the disparity and these issues slips of printed out 
paper  (250mm x 80mm) containing laboratory readings for the biochemical markers of DKA 
were added to the patient file. Some were stapled to the ICU sheet, others stapled together in 
an orderly fashion, and finally some were just placed in the patient file. This is important as 
in instances where the DKA tables were not filled out as these small paper slips were the only 
source of information.  
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4.0 CONCLUSION 
In terms of treatment of diabetic ketoacidosis, Milwaukee protocol has been shown to 
be a successful and safe treatment strategy (when performed correctly) at Rebro hospital, 
over the period of 01.01.2009 – 30.06.2014.  There was a 100% success rate in the treatment 
of DKA using the Milwaukee protocol. Execution of MP at the hospital is generally very 
effective but there are areas where further improvements can be made.  
 All DKA paediatric patients admitted to Rebro hospital should be treated only in the 
paediatric ICU. Policy with clear pro forma should be developed with a hospital wide MP 
algorithm and standardised exit criterion. Additionally, it is the author’s recommendation that 
templates be designed to create quick and simple DKA forms which can be readily filled out 
and followed. An integrated computer system that automatically logs DKA data to this form 
would save time and decrease human error in the process.  
Limitations of the study included absent data from medical files and inadequate 
follow up, illegible handwriting, different formatting of patient files and the author’s 
knowledge of Croatian.  
  Efficacy is defined as “the ability to produce a desired or intended result” (Oxford 
dictionaries 2014) and in that respect the efficacy of DKA treatment at Rebro hospital has 
been of excellent standards over the course of this review period. Further funding or 
modernisation of the ICU department can only bring greater success and cost savings.  
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